Hamilton Lane Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Hamilton Lane Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-34,208	Closed	-$1K	–	74
2022 Q4	$1K	Buy	+34,208	New	+$5.61K	﹤0.01%	68

Hamilton Lane Advisors's PHAS Position: Q1 2023 in Review

Hamilton Lane Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2023, closing a stake of 34,208 shares — an estimated $1K sold.

Hamilton Lane Advisors first reported a position in PHAS in Q4 2022 and held it in 1 quarter. The position peaked at $1K in Q4 2022. 0 funds tracked by Wall St. Rank hold PHAS as of Q1 2023.

Hamilton Lane Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Hamilton Lane Advisors sold 34,208 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $1K.
Hamilton Lane Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Hamilton Lane Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q4 2022.
0 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Hamilton Lane Advisors's 13F filing for Q1 2023, filed 2 May 2023.